公开(公告)号：US20230002373A1

公开(公告)日：2023-01-05

申请号：US17766158

申请日：2020-10-02

申请人： IFM Due, Inc.

发明人： Hans Martin Seidel ,  William R. Roush ,  Jason Katz ,  Shankar Venkatraman

IPC分类号： C07D471/04 ,  C07D497/04 ,  C07D498/04

摘要： This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20220388957A1

公开(公告)日：2022-12-08

申请号：US17422397

申请日：2020-01-16

申请人： IFM Due, Inc.

发明人： Hans Martin Seidel ,  William R. Roush ,  Shankar Venkatraman

IPC分类号： C07D209/40 ,  A61K31/404 ,  C07D471/04 ,  A61K31/437 ,  A61K31/415 ,  C07D231/42 ,  C07D498/04 ,  A61K31/5383 ,  A61K31/4439 ,  A61K31/4545 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12

摘要： This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20220024919A1

公开(公告)日：2022-01-27

申请号：US17376823

申请日：2021-07-15

申请人： IFM Due, Inc.

发明人： Shankar Venkatraman ,  Jason Katz ,  William R. Roush ,  Hans Martin Seidel

IPC分类号： C07D471/04 ,  C07D405/14 ,  C07D403/04 ,  C07D403/14 ,  C07D401/14 ,  C07D493/08

摘要： This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20200172534A1

公开(公告)日：2020-06-04

申请号：US16460381

申请日：2019-07-02

申请人： IFM Due, Inc.

发明人： William R. Roush ,  Shankar Venkatraman ,  Gary Glick ,  Hans Martin Seidel

IPC分类号： C07D471/04

摘要： This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20240122903A1

公开(公告)日：2024-04-18

申请号：US18266189

申请日：2021-12-21

申请人： IFM DUE INC.

发明人： Gary Glick ,  Anthony William Opipari, Jr. ,  Hans Martin Seidel

IPC分类号： A61K31/4184 ,  A61K31/18 ,  A61K31/185 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4188 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/427 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/519

CPC分类号： A61K31/4184 ,  A61K31/18 ,  A61K31/185 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4188 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/427 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/519

摘要： Provided herein are methods of treating a subject, such as a subject that has cancer, that include administering a therapeutically effective amount of a STING antagonist or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having: (I) a cancer cell having one or both of (i) decreased TREX1 level and/or activity, and (ii) increased cGAS/STING signaling pathway activity, e.g., as compared to a reference level, and/or (II) an elevated level of cGAMP in a serum or tumor sample obtained from the subject, e.g., as compared to a reference level.

公开(公告)号：US20240051970A1

公开(公告)日：2024-02-15

申请号：US18266156

申请日：2021-12-16

申请人： IFM Due, Inc.

发明人： Shankar Venkatraman ,  Jason Katz ,  William R. Roush ,  Hans Martin Seidel

IPC分类号： C07D498/04 ,  C07D495/04 ,  C07D403/12 ,  C07D491/052 ,  C07D471/04 ,  C07D403/14 ,  C07D407/14 ,  C07D409/14 ,  A61P37/04

CPC分类号： C07D498/04 ,  C07D495/04 ,  C07D403/12 ,  C07D491/052 ,  C07D471/04 ,  C07D403/14 ,  C07D407/14 ,  C07D409/14 ,  A61P37/04

摘要： This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20240041843A1

公开(公告)日：2024-02-08

申请号：US18266169

申请日：2021-12-21

申请人： IFM Due, Inc.

发明人： Gary Glick ,  Anthony William Opipari, Jr. ,  Hans Martin Seidel

IPC分类号： A61K31/437 ,  A61K31/415 ,  A61K31/4439 ,  A61K31/427 ,  A61K31/4155 ,  A61K31/18 ,  A61K31/167 ,  A61K31/445 ,  A61K31/404 ,  A61K31/454 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/428 ,  A61K31/4725 ,  A61K31/4709 ,  A61K31/4188 ,  A61K31/5377 ,  A61K31/496

CPC分类号： A61K31/437 ,  A61K31/415 ,  A61K31/4439 ,  A61K31/427 ,  A61K31/4155 ,  A61K31/18 ,  A61K31/167 ,  A61K31/445 ,  A61K31/404 ,  A61K31/454 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/428 ,  A61K31/4725 ,  A61K31/4709 ,  A61K31/4188 ,  A61K31/5377 ,  A61K31/496

摘要： Provided herein are methods of treating a subject, such as a subject that has cancer, that include administering a therapeutically effective amount of a STING antagonist or a cGAS inhibitor or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having decreased ATR level and/or activity in a tumor sample obtained from the subject as compared to a reference level.

公开(公告)号：US20230250106A1

公开(公告)日：2023-08-10

申请号：US18015853

申请日：2021-07-15

申请人： IFM Due, Inc.

发明人： Shankar Venkatraman ,  Jason Katz ,  William R. Roush ,  Hans Martin Seidel

IPC分类号： C07D491/107 ,  C07D401/14 ,  C07D401/12 ,  C07D209/40 ,  C07D403/12 ,  C07D471/04 ,  C07D405/14 ,  C07D403/04 ,  C07D413/12

CPC分类号： C07D491/107 ,  C07D401/14 ,  C07D401/12 ,  C07D209/40 ,  C07D403/12 ,  C07D471/04 ,  C07D405/14 ,  C07D403/04 ,  C07D413/12

摘要： This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20230167057A1

公开(公告)日：2023-06-01

申请号：US17884933

申请日：2022-08-10

申请人： IFM Due, Inc.

发明人： Shankar Venkatraman ,  Jason Katz ,  William R. Roush ,  Hans Martin Seidel

IPC分类号： C07D209/40 ,  A61K45/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D401/14 ,  C07D471/04 ,  C07D403/06 ,  C07D417/12 ,  C07D487/08

CPC分类号： C07D209/40 ,  A61K45/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D401/14 ,  C07D471/04 ,  C07D403/06 ,  C07D417/12 ,  C07D487/08 ,  C07B2200/05

摘要： This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20230127839A1

公开(公告)日：2023-04-27

申请号：US17789694

申请日：2020-12-30

申请人： IFM Due, Inc.

发明人： Hans Martin Seidel ,  William R. Roush ,  Shankar Venkatraman ,  Jason Katz

IPC分类号： C07D401/14 ,  C07D401/12 ,  C07D209/40 ,  C07D413/14 ,  C07D491/107 ,  C07D405/14 ,  C07D403/12 ,  C07D498/08

摘要： This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.